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Amplification of the human epidermal growth factor receptor 2 (HER2) is a prognostic marker for poor clinical
outcome and a predictive marker for therapeutic response to targeted therapies in breast cancer patients. With the
introduction of anti-HER2 therapies, accurate assessment of HER2 status has become essential. Fluorescence in situ
hybridization (FISH) is a widely used technique for the determination of HER2 status in breast cancer. However, the
manual signal enumeration is time-consuming. Therefore, several companies like MetaSystem have developed
automated image analysis software. Some of these signal enumeration software employ the so called “tile-sampling
classifier”, a programming algorithm through which the software quantifies fluorescent signals in images on the
basis of square tiles of fixed dimensions. Considering that the size of tile does not always correspond to the size of
a single tumor cell nucleus, some users argue that this analysis method might not completely reflect the biology of
cells. For that reason, MetaSystems has developed a new classifier which is able to recognize nuclei within tissue
sections in order to determine the HER2 amplification status on nuclei basis. We call this new programming
algorithm “nuclei-sampling classifier”. In this study, we evaluated the accuracy of the “nuclei-sampling classifier” in
determining HER2 gene amplification by FISH in nuclei of breast cancer cells. To this aim, we randomly selected
from our cohort 64 breast cancer specimens (32 nonamplified and 32 amplified) and we compared results obtained
through manual scoring and through this new classifier. The new classifier automatically recognized individual
nuclei. The automated analysis was followed by an optional human correction, during which the user interacted
with the software in order to improve the selection of cell nuclei automatically selected. Overall concordance
between manual scoring and automated nuclei-sampling analysis was 98.4% (100% for nonamplified cases and
96.9% for amplified cases). However, after human correction, concordance between the two methods was 100%.
We conclude that the nuclei-based classifier is a new available tool for automated quantitative HER2 FISH signals
analysis in nuclei in breast cancer specimen and it can be used for clinical purposes.
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The human epidermal growth factor receptor 2 (HER2)
gene is located on chromosome 17 and encodes a trans-
membrane tyrosine kinase receptor protein [1]. HER2
gene amplification and receptor overexpression, which
occur in 15% to 20% of human breast cancers, are im-
portant prognostic markers for poor prognosis, includ-
ing a more aggressive disease and a shorter survival [2].
Moreover, HER2-positive status is a predictive marker of
response to trastuzumab therapy in both metastatic and
adjuvant settings [3,4]. An accurate evaluation of HER2
status is therefore crucial for identification of patients
who would most likely benefit from targeted anti-HER2
therapies. Currently, there are several Food and Drug
Administration (FDA)-approved methods to evaluate
HER2 status, such as immunohistochemical (IHC) as-
sessment of HER2 protein expression or evaluation of
HER2 gene amplification using in situ hybridization
(ISH), most commonly, fluorescent ISH (FISH) [5,6].
FISH assay is considered to be one of the reference
methods for HER2 evaluation in breast cancer, as it ac-
curately predicts response to trastuzumab therapy [7].
Patients are eligible for trastuzumab therapy when their
breast cancer specimens are positive at IHC (i.e. 3+)
and/or amplified at FISH (ratio > 2.2). However, patients
whose tumor specimen is equivocal at FISH (ratio be-
tween 1.8 and 2.2) but whose ratio is ≥ 2.0 represent also
potential candidates for targeted treatment.
The classical evaluation method for gene amplifica-
tion, the manual signal enumeration by visual esti-
mation, is a rather time-consuming analysis. Therefore,
several companies have developed automated signal
quantification systems, which operate through a com-
puter with scanning and image analysis software like
Metafer 4 produced by MetaSystems [8,9]. The pro-
gramming algorithm (the so called “classifier”) currently
used by the latter determines the ratio between the aver-
age copy number for HER2 to average copy number for
chromosome 17 (CEP17) on the basis of equi-sized
square tiles [10]. This programming algorithm is defined
as “tile-sampling classifier”. However, as the size of tile
does not always correspond to the size of a single tumor
cell nucleus, some postulate that results obtained might
therefore not completely reflect the biology of single
cells. To encounter this statement, MetaSystems have
recently developed a new programming algorithm, the
“nuclei-sampling classifier”, which is able to automatic-
ally quantify fluorescent signals in nuclei within tissue
sections. In this study, we have compared results
obtained with the reference method, the manual scor-
ing, with those obtained with the new nuclei-sampling
classifier from MetaSystems in 64 clearly nonamplified
(n = 32) and clearly amplified (n = 32) breast cancer
specimens.Material and methods
Case selection
A total of 4641 invasive breast cancer cases were identi-
fied among all specimens that were examined by FISH
between 2009 and 2012 at the Service de Pathologie at
CHU-Hôpital du Saint-Sacrement, Québec, Canada. Of
these examined cases, 3802 were nonamplified, 636 were
amplified and 203 were equivocal. After Ethical Review
Board approval, we randomly selected 32 clearly nonam-
plified and 32 clearly amplified cases among all nonam-
plified (n = 3802) and amplified (n = 636) cases from our
cohort and 32 cases among all equivocal cases (n = 203).
Fluorescence in situ hybridization
HER2 gene copy number was evaluated using the FDA-
approved PathVysion™ HER2 DNA Probe kit (Abbott
Molecular, Des Plaines, IL/ Inter Medico, Markham,
Canada), according to manufacturer’s directions. Briefly,
deparaffinized 4-μm sections were immersed in 0.2 N HCl
for 20 minutes. Slides were placed in pre-treatment solu-
tion at 98°C for 30 minutes and then subjected to protease
digestion at 37°C for 5 minutes. Slides were hybridized
with PathVysion HER2 DNA probe mixture containing a
HER2 DNA probe (labeled with Spectrum Orange) and a
CEP17 DNA probe (labeled with Spectrum Green). The
CEP17 DNA probe allows for a correction of HER2 gene
copy number to the number of copies of chromosome 17.
Slide glass coverslips were applied and sealed with rubber
cement. Slides were then denatured at 74°C for 2 minutes
and hybridized overnight at 37°C in a humidified hybri-
dization chamber (ThermoBrite™, Abbott Molecular/
DAKO, Glostrup, Denmark). On the following day, slides
were washed in a post-hybridization buffer at 73.5°C for
2 minutes and dried in the dark. Nuclei were subsequently
counterstained with 10 μL of 4’,6-diamidino-2-phenylin-
dole (DAPI). Slides were stored in the dark at 4°C until
signal enumeration.
Manual scoring (reference method)
Analysis of fluorescent signals were performed with an
epifluorescence microscope Axio Imager M1 (Zeiss,
Göttingen, Germany), equipped with a triple-band filter
(DAPI/green/orange). Slides were visually scored accord-
ing to the protocol described in PathVysion HER2 pack-
age insert. Briefly, slides were first analyzed at low
magnification using a DAPI filter to identify areas of in-
vasive carcinoma showing optimal tissue digestion and
non-overlapping nuclei within tumor areas selected by a
pathologist. Slides were analyzed by trained technolo-
gists, and results were validated by two breast patholo-
gists with experience in FISH interpretation (SJ or CC).
Results were reported according to the ASCO/CAP and
Canadian HER2 scoring guidelines [5,6]. Specimens with
a HER2/CEP17 ratio of > 2.2 were considered amplified,
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equivocal, while specimens with a ratio of <1.8 were
considered nonamplified [5,6]. Average copy numbers of
HER2 and CEP17 from at least 20 randomly selected nu-
clei, each with at least one HER2 and one CEP17 signal,
from different areas of the invasive carcinoma were
counted and HER2/CEP17 ratio calculated. For equivo-
cal cases, ratios were calculated from at least 60 tumorFigure 1 Image analysis of fluorescence signals. A). Automated quantit
overlapping square tile were placed on DAPI-counterstain image in order t
single nucleus or portions of one or more nuclei. The software effectuated
the automated nuclei-sampling classifier. The classifier automatically recogn
Figure 1A). Nuclei that were automatically recognized and considered in th
recognized but not considered in the analysis had a white outline. The sof
the automated image analysis, the user could improve the selection of aut
particular case, some nuclei that were not yet considered during the autom
automatically selected nuclei were deleted and some overlapping nuclei wcells. Equivocal cases were counted by two independent
trained technologists and reviewed by the pathologists of
this study.
Tile-sampling classifier
Automated fluorescence signal analysis was performed
through the FDA-approved MetaSystems™ image analy-
sis system. The capture station is composed of a scanner,ative image analysis through the tile-sampling classifier. Non-
o maximize the nuclear material covered. Each tile may contain a
the spot count in each tile. B). Quantitative image analysis through
ized individual nuclei in counterstain image (same image as in
e analysis showed green outlines, while nuclei that were automatically
tware effectuated spot count in each nucleus. C). After completion of
omatically selected nuclei via interaction with the software. In this
atic segmentation (Figure 1B) were selected by the user, some
ere divided (yellow line between two overlapping nuclei).
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era with Mercury Lamp HBO 100 and a computer with
the microscope scanning and analysis software Metafer 4
with “tile-sampling” method (MetaSystems, Altussheim,
Germany). The Local Area Network (LAN)-connected
capture station worked on PC Intel Core2 Duo CPU
E8500 3.16 GHz , 3.25 GB of RAM server, with 1280x1024
pixel size. After selection of 5 to 10 non-overlapping fields
of infiltrating carcinoma by trained technologists within
tumor areas identified by a pathologist, fields’ images were
automatically captured and analyzed by the software. In
analogy to manual scoring, representative images with op-
timal tissue digestion and non-overlapping nuclei were
selected. All images were captured at 400x microscope
magnification. Minimal integration time was 0.04 seconds.
Image size was 1088 × 880 pixels × 8 bits (between 40 and
90 MB, in MetaSystems format. TRN, with 255 gray
levels). A classifier is a programming algorithm which
defines how images are captured and analyzed by the soft-
ware. The classifier used for this type of analysis, the “tile-
sampling classifier”, permitted extensive tumor sampling
by placing non-overlapping equi-sized square tiles in coun-
terstain images (DAPI image). Square tiles were 71 pixels
in size and were generally on the order of the size of one
or two nuclei. Classifier placed tiles in regions of images
where nuclear material was the highest, in order to include
as much nuclear material and as little empty space as pos-
sible in tiles. Classifier recognized these regions through
the DAPI filter. Aim of this strategy was to maximize the
total fluorescence intensity covered (Figure 1A) [10]. Cap-
tured images underwent image processing through several
filters (Gaussian smoothing filter, TopHat filter and
Laplace) and application of a counterstain mask [10].
Image analysis software carried out FISH spot counting
through analysis of fluorescence signals present within tiles
using several signal colour channels. HER2 spots were
recognized through Spectrum Orange filter and were
defined as object with an area of 0.05 μm2, a distance of
0.8 μm between objects and an intensity of 33% after
image processing. CEP17 spots were recognized through
Spectrum Green filter and were defined as object with an
area of 0.18 μm2, a distance of 0.5 μm between objects and
an intensity of 30% after image processing. Single tiles
were rejected by the classifier when less than 40% of the
surface was occupied with nuclei, or when they contained
only one fluorescent signal (only one orange or only one
green fluorescent signal). Cases were rejected when they
contained less than 32 tiles. Time consumption for analysis
by tile-sampling classifier on a local station was between 3
and 5 minutes. Image analysis software calculated signal
ratio by dividing the average HER2 and CEP17 spot num-
ber per tile [10]. Results were reported using the same
scoring guidelines as for manual scoring (nonamplified,
equivocal, amplified).Nuclei-sampling classifier
The same images produced during the tile-sampling
analysis were analyzed with a new Metafer 4 classifier
(MetaSystems). The new classifier was tested on the ana-
lysis station, which was composed of a PC Intel Core2
Duo CPU E4600 2.4 GHz, 1 GB of RAM server with
1280x1024 pixel size. Analysis station was LAN-
connected with capture station. Size of images was iden-
tical as for the tile-sampling analysis, as we used the
same images (1088 × 880 pixels × 8 bits). This new clas-
sifier automatically recognized individual cells in coun-
terstain image through segmentation of nuclei, i.e. the
outlining of individual nucleus. Nuclei were recognized
by the classifier when they had an object area between
12 μm2 and 400 μm2 with certain roundness in DAPI
images. Color of nuclei outlines informed the user of
which nuclei have been considered for analysis. Nuclei
that were automatically segmented and considered in
analysis showed green outlines, while pre-segmented nu-
clei (nuclei that were automatically segmented but not
considered in the analysis) were represented by a white
outline (Figure 1B). The software recognized appropriate
nuclei for analysis on the basis of size and shape of nu-
clei and on quality of fluorescent signals. In this paper,
we defined this method as the “nuclei-sampling analysis”
to differentiate it from the “tile-sampling analysis”. The
nuclei-sampling analysis was performed blinded from
results obtained by manual scoring and tile-sampling
analysis.
This automated nucleus segmentation was followed by
an optional human correction, in which the user inter-
acted with interface in order to improve selection of cell
nuclei automatically selected by the software. This op-
tional interactive phase required an interactive touch
screen (e.g. the WACOMW DTU-2231, 1920 × 1080 pi-
xels, MetaSystems). The interaction was performed
using a mouse or an interactive pen display. The user
utilized the following interaction options: addition of nu-
clei (not yet considered during the automated segmenta-
tion) to be analyzed, selection of pre-segmented nuclei
(nuclei that were recognised by the software but not
considered in the analysis), deletion of automatically
selected nuclei, partition of overlapping nuclei, or con-
nection of separated objects (for instance parts of the
same nucleus that were accidentally separated during
the automated segmentation) (Figure 1C). Any of these
operations led to automatic updates of signal ratio
results. The software carried out FISH spot counting for
both the automated and the human corrected nuclei-
sampling analyses in the same way as for the tile-
sampling classifier. Again, results for both automated
and human corrected nuclei-sampling analyses were
reported using the same scoring guidelines as for manual
scoring (nonamplified, equivocal, amplified).
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Validation of the nuclei-sampling classifier in
nonamplified and amplified breast cancer specimens
In order to validate the new classifier, we examined the
concordance of results obtained by manual scoring and
by nuclei-sampling analysis in 32 clearly nonamplified
and 32 clearly amplified cases, chosen randomly in our
cohort of breast cancer patients. Our selection criteria
fulfill the requirements of the ASCO/CAP and Canadian
recommendations for HER2 testing in breast cancer for
the validation of a new test. Indeed, these guidelines rec-
ommend that a new test has to be compared with a
reference test in at least 25 samples, ideally by using
50% cases that are clearly positive and 50% cases that
are clearly negative [5,6]. Table 1 shows the comparison
between results obtained by manual scoring, the refer-
ence method, and the tile-sampling analysis and nuclei-
sampling analysis in these 64 breast cancer specimens.
For the nuclei-sampling analysis, concordance between
reference method (manual scoring) and results obtained
with the automated analysis (before human correction)
was 100% for nonamplified cases and 96.9% for ampli-
fied cases. Overall concordance rate was 98.4%. One case
out of 32 considered as amplified by manual scoring was
considered as borderline equivocal (ratio of 2.2) with the
nuclei-sampling analysis. However, after human correc-
tion, concordance between manual scoring and nuclei-
sampling analysis was 100% for both the nonamplified
and the amplified cases. Concordance between manual
scoring and tile-sampling analysis was 100% for both the
nonamplified and the amplified cases.
Determination of the accuracy of the nuclei-sampling
classifier on special specimens
In a closer analysis of the randomly selected amplified
cases, we observed that all examined cases were ampli-
fied with Homogeneously Staining Regions (HSR). HSR
are large clusters of HER2 fluorescence signals indicating
the presence of HER2 gene amplification in tandem
repeats (Figure 2A). In samples in which HSR occurred
and individual signals could not be counted, the software
adopted a different spot counting analysis, which evalu-
ated the signal area in the HER2 channel instead of indi-
vidual spot counts [10]. As in the population of this
study approximately 4% of amplified cases do not show





Nonamplified Equivocal Amplified Nonamplified
Nonamplified 32 0 0 32
Amplified 0 0 32 0classifier also on these less common cases. In our co-
hort, we identified 28 amplified cases without HSR. Al-
though cases were recognized as amplified without HSR
on the basis of results obtained through tile-sampling
analysis, manual scoring represented the reference
method also for these cases. Results for amplified cases
without HSR are summarized in Table 2. Of these 28
amplified cases without HSR, 21 cases were classified as
amplified with the automated nuclei-sampling analysis,
and this number increased to 24 after human correction.
Concordance between manual scoring and nuclei-
sampling analysis was 75% (21/28). Of the 7 discordant
cases that showed a ratio ≤ 2.2 with the automated
nuclei-sampling analysis, 4 had a ratio between 2.0 and
2.2, whereas 3 had a ratio smaller than 2.0. After human
correction, the concordance between the manual scoring
and the nuclei-sampling analysis was 86% (24/28). Of
the 4 discordant cases that showed a ratio ≤ 2.2 with
nuclei-sampling analysis after human correction, 3 cases
showed a ratio between 2.0 and 2.2, whereas 1 case
showed a ratio smaller than 2.0. Concordance between
tile-sampling analysis and manual scoring method was
100%. This result is not surprising, as the samples with-
out HSR were identified on the basis of results obtained
through tile-sampling analysis.
Determination of the accuracy of the nuclei-sampling
classifier on equivocal specimens
To further evaluate the accuracy of the new classifier, we
examined 32 equivocal cases. However, only 29 cases have
been analyzed, since in 3 cases, images were of very poor
quality. Equivocal cases constitute approximately 5% of
our cohort. Results for equivocal cases are summarized in
Table 3. Of these 29 equivocal cases, 9 cases were classi-
fied as equivocal, 19 as nonamplified and one case was
classified as amplified with tile-sampling analysis. With
nuclei-sampling analysis after human correction, 17 cases
were classified as equivocal, 11 as nonamplified and one
case was classified as amplified. Concordance between
manual scoring and tile-sampling analysis was 31% (9/29),
whereas the concordance between manual scoring and
nuclei-sampling analysis after human correction was 59%
(17/29). Among the 15 cases whose ratio was ≥ 2.0 at the
manual scoring, 3 (20%) were also ≥ 2.0 at the tile-
sampling method, whereas 6 out of these 15 cases (40%)
were ≥ 2.0 at the nuclei-sampling method after humanfor nonamplified and amplified cases (n = 64)
Nuclei-sampling analysis
omated analysis After human correction
Equivocal Amplified Nonamplified Equivocal Amplified
0 0 32 0 0
1 31 0 0 32
Figure 2 HER2 fluorescence in situ hybridization in amplified cases. A). Amplified case showing Homogeneously Staining Regions (HSR). HSR
are large clusters of HER2 fluorescence signals indicating the presence of HER2 gene amplification in tandem repeats. B). Amplified case without
HSR. HER2 signals are identifiable as single spots.
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the manual scoring, 13 (93%) were also < 2.0 at the tile-
sampling method, whereas 12 out of these 14 cases (86%)
were < 2.0 at the nuclei-sampling method after human
correction.
Reproducibility of results
All cases analyzed in this study (clearly nonamplified,
clearly amplified, equivocal and amplified cases without
HSR) were assessed blindly by a second independent ob-
server. The results obtained by the two observers were
similar (data not shown).
Discussion
Our results showed an excellent concordance between
manual scoring, our reference method, and nuclei-
sampling analysis for clearly nonamplified and clearly
amplified cases. Indeed, the concordance of results for
nonamplified cases was 100%, both for the automated
and the human corrected nuclei-sampling analyses. For
amplified cases, the concordance between the two meth-
ods was 96.9% for the automated nuclei-sampling ana-
lysis and rose to 100% following human correction.
These concordance rates with manual scoring results
fulfill the ASCO/CAP requirements of concordance
greater than 95% for clearly amplified and nonamplified
cases [6].
Our results are consistent to those obtained by Theodo-





< 2.0 2.0 – 2.2 > 2.2 < 2.0
> 2.2 0 0 28 3
HSR = Homogeneously Staining Regions.the utility of an image analysis software (EIKONA3D,
Alpha Tec Ltd) for the evaluation of HER2 amplification
in nuclei in 100 breast cancer cases from two institutions.
Similar to the analysis software presented here, the user
had the possibility to manually correct the results obtained
through the automated nuclei segmentation. They found a
very good overall concordance (92.8%) between the results
obtained by manual scoring by an expert and those
obtained with the image analysis software. Similar to our
results, the concordance for nonamplified cases was 100%,
whereas the concordance for amplified cases was lower,
74.1% [11].
In this work, we validated the new Metafer 4 classifier
in 64 breast cancer specimens (32 nonamplified and 32
amplified cases), chosen randomly among eligible clearly
nonamplified and amplified cases of our cohort, as
required from the ASCO/CAP and the Canadian guide-
lines for HER2 testing in breast cancer for validation of
a new test. Accordingly to these recommendations, a
new test has to be compared with the reference test in
at least 25 samples, ideally by using 50% cases unequivo-
cally positive and 50% cases unequivocally negative [5,6].
The new classifier evaluated here was able to recognize
cell nuclei on the image and therefore to calculate HER2
FISH ratio on nucleus basis. Moreover, this new classi-
fier allowed the user to interact with the software during
an optional interactive phase, in order to improve the se-
lection of cells automatically selected by the software. In
this study, we defined this method as “nuclei-samplingfor amplified cases without HSR (n = 28)
Nuclei-sampling analysis
mated analysis After human correction
2.0 – 2.2 > 2.2 < 2.0 2.0 – 2.2 > 2.2
4 21 1 3 24
Table 3 Comparison of results obtained by different methods for equivocal cases (n = 29)
Manual
scoring
Tile-sampling analysis Nuclei-sampling analysis, after human correction
< 1.8 ≥ 1.8 – < 2.0 2.0 – 2.2 > 2.2 < 1.8 ≥ 1.8 – < 2.0 2.0 – 2.2 > 2.2
≥ 1.8 - < 2.0 12 1 1 0 7 5 1 1
2.0 – 2.2 7 5 2 1 4 5 6 0
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which was performed with the Metafer 4 classifier cur-
rently used. This classifier, in fact, calculated HER2 FISH
ratio on the basis of equi-sized tiles placed by the soft-
ware on images. In order to validate this new classifier,
we compared results obtained through manual scoring
of slides, considered as the reference method, with those
obtained through nuclei-sampling analysis. Moreover, we
analyzed the accuracy of both the automated and the
human corrected nuclei-sampling analyses.
As all randomly selected amplified cases analyzed in
this study were amplified with HSR, we decided to
evaluate the accuracy of this new classifier on the less
common amplified cases without HSR. These cases
represented indeed about 4% of all amplified cases in
our cohort of breast cancer patients. For the 28 cases
without HSR that we have analyzed, concordance be-
tween manual scoring and automated nuclei-based
method was 75%. After human correction, concordance
between the two methods rose to 86%. Considering that
patients whose specimen is equivocal at FISH (ratio be-
tween 1.8 and 2.2) but whose ratio is ≥ 2.0 represent
also potential candidates for trastuzumab treatment, 4
patients out of 7 discordant cases at the automated
nuclei-sampling analysis, and 3 cases out of 4 discordant
cases at the nuclei-sampling analysis after human cor-
rection would therefore be eligible to receive a targeted
treatment. We noticed that some discordant cases were
polysomic or monosomic (4 out of 7 discordant cases)
and we postulate that this aneuploidy status could ex-
plain the discordance. It has been reported that bio-
logical variance reduces sampling efficiency [12]. Indeed,
higher biological variance associated with aneuploidy
status could have had an impact on the spot counting by
the software and this could explain the discrepancy with
results obtained by manual scoring. Moreover, quality of
the images of some discordant cases (2 out of 7 discord-
ant cases) was poor (cell nuclei were blurred in the
image), which could also be an additional explanation
for this discrepancy.
With the aim to further analyse the accuracy of the
new classifier, we also examined equivocal cases, which
represent about 5% of our cohort population. Overall
concordance between manual scoring and tile-sampling
method was 31%, whereas concordance between manual
scoring and nuclei-sampling method after human cor-
rection was 59%. If equivocal cases were splitted in thosewith ratio ≥ 2.0 and those with ratio < 2.0, we noticed
that twice as many cases were correctly classified with a
ratio ≥ 2.0 using nuclei-sampling method after human
correction as compared to tile-sampling method. So
even if concordance between manual scoring and nuclei-
sampling method was not optimal, these results suggest
that nuclei-sampling method is more reliable than tile-
sampling method for the identification of patients who
could potentially benefit from targeted anti-HER2 ther-
apies. Similar to the amplified cases without HSR, we
also noticed that some discordant cases were aneuploid
(4 out of 12 discordant cases). Also, in 2 out of 12 dis-
cordant cases the quality of images was poor (cell nuclei
were blurred in images).
Tile-sampling method has been developed by Meta-
Systems and other companies in order to overcome the
difficulties that are frequently encountered when fluores-
cent signals are enumerated via automated image ana-
lysis software. Firstly, reliable separation of overlapping
nuclei in tissue sections is very difficult, especially in
dense packed tissues like breast cancer. Secondly, it is
arduous for image analysis software to automatically dis-
tinguish distinct cell populations (normal and tumor
cells) present in analyzed fields. To overcome these diffi-
culties, the Metafer 4 software places non-overlapping
tiles of equal size on images in order to cover the major-
ity of nuclear material and therefore quantify fluorescent
signals. Moreover, a ratio estimation algorithm was in-
troduced with the aim to improve the accuracy of results
of the automated analysis in samples in which distinct
cell populations are present [10,13].
Although the tile-sampling analysis is in general well
performing [8,9], the nuclei-based analysis offers some
advantages compared to the tile-based analysis. Firstly,
the way in which the new classifier selects nuclei for
analysis coincides better to what the user does when the
user is analyzing a sample. Whereas the nuclei-sampling
analysis recognizes cell nuclei, the tile-sampling analysis
places equi-sized tiles on the image. In addition, as the
size of tile does not always correspond to the size of a
single nucleus, nuclei are often truncated during tile-
sampling. As a consequence, one single tile may contain
signals from multiple nuclei or only part of a nucleus.
This can be disadvantageous especially in cases of
chromosome 17 monosomy or polysomy, where exact
number of CEP17 signal per cell is relevant. Secondly,
the nuclei-based analysis offers the advantage that the
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been automatically selected by the software through ac-
tive interaction with the software. During the interactive
phase, the user can add nuclei that were not considered
during the automated selection, delete unsuitable nuclei,
divide overlapping nuclei or connect separated pieces of
the same nucleus. This optional, interactive phase requires
additional time, in average 7 minutes for equivocal cases
and amplified cases without HSR and 4 minutes for non-
amplified cases and amplified cases with HSR, but it is
very helpful and effective especially in difficult cases, for
instance in samples with abundant stroma or intermixed
normal cells. In fact, we observed a better concordance
between results obtained by the reference method and
those obtained with the nuclei-based analysis after the
interactive phase, compared to results obtained with the
automated analysis. Theodosiou and collaborators ob-
served similar results using a similar method. In their
hand, manual correction required up to 5 minutes for
each case (nonamplified and amplified cases) and it was
particularly useful in cases with low image quality [11].
We noticed that among all functions that the user could
choose during the interactive phase, the delete function
was the most effective one. In fact, when discordant cases
were evaluated blindly by a second independent observer
who used exclusively the delete function, results obtained
by the two observers were similar (data not shown). We
may therefore conclude that the delete function is very ef-
fective in improving the results obtained with the auto-
mated nuclei-based analysis. Moreover, the time necessary
for human correction can additionally be reduced if only
the delete function is used during the interactive phase
(6 minutes in average for equivocal cases and amplified
cases without HSR). The automated nuclei-sampling ana-
lysis required between 3 and 5 minutes per case, depend-
ing on the cellularity of images. Our image analysis
software is slower compared to others, for example
Matlab, which required 3.5 seconds for analysis of a single
image on local server [14]. As we analyzed between 5 and
10 images for each case, Matlab would have taken be-
tween 17.5 and 35 seconds to evaluate a case.
In this study, the reference method was represented by
the manual scoring of specimen. A closer examination
of nuclei automatically selected by the software during
nuclei-based analysis allowed us to observe how the user
can also be biased when the user is analysing a case. In
particular, human eyes have a tendency to pay more at-
tention to those cell nuclei in which more fluorescent
signals are present. One could therefore argue that
human brain considers those nuclei more attractive and
preferentially chooses them during the manual signal
enumeration. Nuclei-based analysis, on the contrary,
selects nuclei on the basis of the shape of cell nuclei and
on quality of fluorescent signals and is therefore more“neutral” in the choice of the nuclei. Therefore, eligible
nuclei that have less fluorescent signals (and may be
judged as less attractive by human brain) are also taken
into account for analysis from software. Opinions on this
topic are divergent. Whereas some underline that soft-
ware do not always select the most appropriate nuclei
for analysis [11], others claim that results obtained with
automated analysis are more accurate especially in amp-
lified and borderline cases, as manual analysis of HER2
signals can only be estimated when probe signals cluster
closely together [15]. Another advantage of image ana-
lysis system over manual scoring is that storing of cap-
tured images allows archiving of cases for future study.
Some limitations are associated with the new classifier.
Accuracy of the new classifier to recognize nuclei is
markedly reduced in images with dense packing of cells
or in images in which DAPI counterstain is blurred. As
mentioned above, results obtained with any quantitative
image analysis software depend tremendously on the
fields chosen by the observer for analysis. If the fields
chosen are not representative of the sample, results
obtained by quantitative image analysis can be rather
different from those obtained through manual scoring.
This issue is common to all diagnostic algorithms. Reli-
able sampling procedure is prerequisite for diagnostic
accuracy in virtual microscopy [12,16].
Standardization of images capture is a central point in
the development of a diagnostic algorithm in virtual mi-
croscopy [17]. In our study, optimal specification for the
capture of images from FISH HER2 slides hybridized with
PathVysion™ HER2 DNA Probe kit (image size, size of
tiles, identification criteria for HER2 and CEP17 spots,
segmentation criteria for nuclei, filtering) has been previ-
ously established using over 400 slides (personal commu-
nication, Ulrich Klingbeil, MetaSystems). Quality of
captured images is in general excellent, since quality and
intensity of fluorescence signals are reproducible and
background is very low. Dissimilar to other algorithms
used in object-related diagnosis [16], fluorescent spot
identification is less problematic. In contrary to other
structures within tissue that are difficult to be recognized,
fluorescent spots are easily identified by the classifier, as
they are mostly of the same size and intensity, except for
HSR cases. However, spot identification is also reliable in
amplified cases with HSR (where spot dimensions can be
more variable), since the software adopted a different
spot-counting analysis (evaluation of the signal area in the
HER2 channel instead of individual spot counts) [10].
Tissue-based diagnosis has been subjected to remar-
kable changes following the introduction of new technolo-
gies. For instance, technological advances in tissue-based
diagnosis allow the implementation of digitized images
into routine clinical pathology. Virtual pathology has se-
veral advantages compared to conventional microscopy.
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images, promotes continuing education as well as inter-
active remote consultation between pathologists [18].
Moreover, it has been reported that analysis of digitized
slides gives results as accurate as that obtained through
conventional microscopy [19,20]. However, one critical
point is whether the diagnostic information contained in
the virtual slides reliably reflect the real whole slide. In this
context, the adopted sampling procedure plays a central
role [12]. This is an important point to consider, when the
efficacy of virtual diagnostic algorithms are compared
[12]. Both the tile-sampling classifier and the nuclei-
sampling classifier are based on a stratified and passive
sampling method as defined in Kayser et al. [12]. However,
whereas the tile-sampling classifier recognizes nuclear ma-
terial through the DAPI filter (and put square tiles on the
image, where the DAPI coloration is the strongest), the
nuclei-sampling classifier recognizes single nuclei within
tissue on the basis of nuclei characteristics, such as nuclei
size and roundness. Spot recognition and spot counting is
effectuated in same way for both methods.
In our clinical context, pathologists share virtual images
and results via a LAN platform. This form of information
sharing represents one of the first steps towards the so
called “Grid technology”. A Grid is an open and dynamic
communication system consisting of connected nodes
(i.e. servers) that are linked together via Internet connec-
tions and share certain communication rules in using
open standards [21]. The Grid technology will also have
an impact on the quality in tissue-based diagnosis as such
implementation will require appropriate standardization
of legal, medical and technological aspects associated with
virtual pathology [17].Conclusions
In summary, we observed an excellent concordance be-
tween results obtained by manual scoring and those by
nuclei-sampling analysis in 32 clearly nonamplified and 32
clearly amplified breast cancer specimens. However, ac-
curate determination of HER2 amplification in equivocal
cases (ratio between 1.8 and 2.2) remains a challenge [5,6].
Manual assessment of these cases, therefore, remains the
standard procedure. We conclude that the new image ana-
lysis software Metafer 4 classifier is a reliable tool to evalu-
ate the unequivocal status of HER2 in breast cancer
specimens and it is ready to be implemented in clinics, as
it offers several advantages compared to the Metafer 4
classifier currently used. Moreover, although more time-
consuming, human correction after the completion of the
automated nuclei-sampling analysis is recommended, es-
pecially in particular cases (like those with abundant
stroma), as this operation leads to an improvement of the
results obtained during the automated analysis.Abbreviations
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